巴西炎症性肠病研究小组关于新冠病毒疫苗接种的立场声明。
BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.
作者信息
Queiroz Natália Sousa Freitas, Teixeira Fábio Vieira, Freire Caio Cesar Furtado, Motta Marina Pamponet, Vasconcellos Marcela Almeida Menezes de, Chebli Liliana Andrade, Saad-Hossne Rogerio
机构信息
Departamento de Gastroenterologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.
Gastrosaúde - Clínica IBD, Marília, SP, Brasil.
出版信息
Arq Gastroenterol. 2021 Jan-Mar;58(1):1-4. doi: 10.1590/S0004-2803.202100000-02.
Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.
大规模疫苗接种是对抗新冠疫情的最佳策略，目前几种新冠病毒疫苗已在多个国家获批紧急使用。在巴西，预计未来几天将批准疫苗，然而对于特定人群，如炎症性肠病（IBD）患者的疫苗接种建议，仍存在潜在担忧。为解决这些问题，巴西炎症性肠病研究小组（GEDIIB）提供了这份实用建议，其中包含针对IBD人群新冠疫苗的关键建议。
Zotero 插件